Cargando…
Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness
Background: Older people (≥60 years old) are particularly vulnerable to influenza virus infection, and vaccine is effective in reducing the disease burden in this population. However, it remains obscure whether their antibody response is lower than those of younger adults (18–60 years old). Thus, th...
Autores principales: | Meng, Ziyan, Zhang, Jiayou, Shi, Jinrong, Zhao, Wei, Huang, Xiaoyuan, Cheng, Li, Yang, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746244/ https://www.ncbi.nlm.nih.gov/pubmed/32347787 http://dx.doi.org/10.1080/21645515.2020.1747375 |
Ejemplares similares
-
Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
por: Huang, Xiaoyuan, et al.
Publicado: (2022) -
Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis
por: Yang, Jing, et al.
Publicado: (2020) -
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial
por: Rümke, Hans C, et al.
Publicado: (2013) -
Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study
por: Fan, Renfeng, et al.
Publicado: (2021) -
Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)